Immuneering Corporation (IMRX)
Largest Insider Buys in Sector
IMRX Stock Price History Chart
IMRX Stock Performance
About Immuneering Corporation
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. …
Insider Activity of Immuneering Corporation
Over the last 12 months, insiders at Immuneering Corporation have bought $477,955 and sold $3.91M worth of Immuneering Corporation stock.
On average, over the past 5 years, insiders at Immuneering Corporation have bought $6.25M and sold $3.91M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BERMAN ANN E (director) — $246,873. Feinberg Peter (director) — $246,771. Zeskind Benjamin J. (PRESIDENT AND CEO) — $55,326.
The last purchase of 25,000 shares for transaction amount of $63,713 was made by Feinberg Peter (director) on 2024‑03‑22.
List of Insider Buy and Sell Transactions, Immuneering Corporation
| 2024-04-01 | Sale | 10 percent owner | 400,000 1.4407% | $2.90 | $1.16M | -40.55% | ||
| 2024-03-22 | director | 25,000 0.0853% | $2.55 | $63,713 | -33.73% | |||
| 2024-03-22 | Chief Accounting Officer | 393 0.0013% | $2.55 | $1,000 | -33.73% | |||
| 2024-03-22 | Chief Business Officer | 3,900 0.0134% | $2.57 | $10,015 | -33.73% | |||
| 2024-03-22 | director | 2,900 0.0099% | $2.55 | $7,385 | -33.73% | |||
| 2024-03-21 | Chief Accounting Officer | 1,107 0.0038% | $2.72 | $3,009 | -38.32% | |||
| 2024-03-20 | CHIEF SCIENTIFIC OFFICER | 7,000 0.0246% | $2.86 | $20,020 | -39.21% | |||
| 2024-03-20 | CHIEF PEOPLE OFFICER | 3,818 0.0135% | $2.88 | $10,993 | -39.21% | |||
| 2024-03-19 | PRESIDENT AND CEO | 20,000 0.0735% | $2.77 | $55,326 | -33.59% | |||
| 2024-03-19 | director | 25,000 0.085% | $2.56 | $64,000 | -33.59% | |||
| 2024-03-18 | director | 57,965 0.1647% | $2.13 | $123,436 | -33.20% | |||
| 2024-03-18 | director | 50,000 0.1588% | $2.38 | $119,058 | -33.20% | |||
| 2024-03-15 | Sale | 10 percent owner | 400,000 1.5312% | $2.14 | $856,400 | -9.95% | ||
| 2024-03-14 | Sale | 10 percent owner | 509,091 1.0954% | $3.72 | $1.89M | -40.34% | ||
| 2022-05-25 | CHIEF SCIENTIFIC OFFICER | 2,551 0.0097% | $3.92 | $10,000 | +74.81% | |||
| 2022-05-17 | GENERAL COUNSEL AND SECRETARY | 1,000 0.0037% | $4.88 | $4,880 | +32.61% | |||
| 2022-05-16 | 7,000 0.0283% | $5.00 | $35,000 | +42.64% | ||||
| 2022-05-12 | CFO, TREASURER | 1,000 0.0033% | $4.42 | $4,420 | +31.29% | |||
| 2022-03-23 | PRESIDENT AND CEO | 3,000 0.0119% | $8.02 | $24,060 | -18.85% | |||
| 2022-03-23 | CHIEF SCIENTIFIC OFFICER | 1,050 0.0041% | $7.91 | $8,306 | -18.85% |
Insider Historical Profitability
| Cormorant Asset Management, LP | 10 percent owner | 2895273 9.3244% | $2.25 | 1 | 3 | <0.0001% |
| Zeskind Benjamin J. | PRESIDENT AND CEO | 2281852 7.3489% | $2.25 | 4 | 0 | <0.0001% |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | 345896 1.114% | $2.25 | 4 | 0 | +2.71% |
| Feinberg Peter | director | 111766 0.36% | $2.25 | 7 | 0 | <0.0001% |
| BERMAN ANN E | director | 67465 0.2173% | $2.25 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| Cormorant Asset Management Lp | $9.52M | 11.11 | 3.3M | -21.62% | -$2.63M | 0.44 | |
| Citadel Advisors LLC | $5.44M | 6.35 | 1.88M | -9.43% | -$566,127.88 | <0.01 | |
| BlackRock | $3.98M | 4.64 | 1.38M | -34.34% | -$2.08M | <0.0001 | |
| The Vanguard Group | $3.48M | 4.06 | 1.2M | +12.09% | +$375,269.42 | <0.0001 | |
| T. Rowe Price | $2.63M | 3.07 | 910,266 | -73.05% | -$7.14M | <0.0001 |